Tocilizumab more effective in reducing rheumatoid arthritis symptoms than adalimumab
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trialLancet. 2013 May 4;381(9877):1541-50. doi: 10.1016/S0140-6736(13)60250-0. Epub 2013 Mar 18
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
326 patients with severe rheumatoid arthritis, with whom methotrexate was deemed inappropriate, were randomized to receive tocilizumab intravenously every 4 weeks plus a placebo subcutaneously every 2 weeks for 24 weeks or adalimumab subcutaneously every 2 weeks plus a placebo intravenously every 4 weeks for 24 weeks, in order to compare the safety and efficacy between the two drugs. After the 24 ...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE